ProfileGDS5678 / 1436013_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 27% 26% 26% 25% 25% 27% 26% 25% 25% 26% 26% 26% 26% 26% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.6437127
GSM967853U87-EV human glioblastoma xenograft - Control 22.600626
GSM967854U87-EV human glioblastoma xenograft - Control 32.6023626
GSM967855U87-EV human glioblastoma xenograft - Control 42.5370125
GSM967856U87-EV human glioblastoma xenograft - Control 52.5371825
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.6888727
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.644226
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.572225
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.5596425
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.5872826
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.586826
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.573526
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.5897126
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.5950526